Literature DB >> 12917399

Alternative splicing of the human cyclin D-binding Myb-like protein (hDMP1) yields a truncated protein isoform that alters macrophage differentiation patterns.

Mario P Tschan1, Kimberlee M Fischer, Vivian S Fung, Farzaneh Pirnia, Markus M Borner, Martin F Fey, Andreas Tobler, Bruce E Torbett.   

Abstract

We have cloned two novel, alternatively spliced messages of human cyclin D-binding Myb-like protein (hDMP1). The known, full-length protein has been named hDMP1alpha and the new isoforms, hDMP1beta and hDMP1gamma. The hDMP1alpha, -beta, and -gamma splice variants have unique expression patterns in normal hematopoietic cells; hDMP1beta mRNA transcripts are strongly expressed in quiescent CD34+ cells and freshly isolated peripheral blood leukocytes, as compared with hDMP1alpha. In contrast, activated T-cells and developing myeloid cells, macrophages, and granulocytes express low levels of hDMP1beta transcripts, and hDMP1gamma is ubiquitously and weakly expressed. Mouse Dmp1 has been shown to activate CD13/aminopeptidase N (APN) and p19ARF gene expression via binding to canonical DNA recognition sites in the respective promoters. Assessment of CD13/APN promoter responsiveness demonstrated that hDMP1alpha but not hDMP1beta and -gamma, is a transcriptional activator. Furthermore, hDMP1beta was found to inhibit the CD13/APN promoter transactivation ability of hDMP1alpha. Stable, ectopic expression of hDMP1beta and, to a lesser extent hDMP1gamma, reduced endogenous cell surface levels of CD13/APN in U937 cells. Moreover, stable, ectopic expression of hDMP1beta altered phorbol 12-myristate 13-acetate-induced terminal differentiation of U937 cells to macrophages and resulted in maintenance of proliferation. These results demonstrate that hDMP1beta antagonizes hDMP1alpha activity and suggest that cellular functions of hDMP1 may be regulated by cellular hDMP1 isoform levels.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12917399     DOI: 10.1074/jbc.M307067200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  41 in total

1.  Tumor suppression by the EGR1, DMP1, ARF, p53, and PTEN Network.

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Cancer Invest       Date:  2018-11-05       Impact factor: 2.176

2.  EAnnot: a genome annotation tool using experimental evidence.

Authors:  Li Ding; Aniko Sabo; Nicolas Berkowicz; Rekha R Meyer; Yoram Shotland; Mark R Johnson; Kymberlie H Pepin; Richard K Wilson; John Spieth
Journal:  Genome Res       Date:  2004-12       Impact factor: 9.043

3.  Stabilization of the p53-DNA Complex by the Nuclear Protein Dmp1α.

Authors:  Robert D Kendig; Fumitake Kai; Elizabeth A Fry; Kazushi Inoue
Journal:  Cancer Invest       Date:  2017-04-13       Impact factor: 2.176

4.  CLEC5A (MDL-1) is a novel PU.1 transcriptional target during myeloid differentiation.

Authors:  Jasmin Batliner; Maria Michela Mancarelli; Mathias Jenal; Venkateshwar A Reddy; Martin F Fey; Bruce E Torbett; Mario P Tschan
Journal:  Mol Immunol       Date:  2010-11-20       Impact factor: 4.407

Review 5.  Role of DMP1 and its future in lung cancer diagnostics.

Authors:  Takayuki Sugiyama; Donna P Frazier; Pankaj Taneja; Rachel L Morgan; Mark C Willingham; Kazushi Inoue
Journal:  Expert Rev Mol Diagn       Date:  2008-07       Impact factor: 5.225

6.  Low DICER1 expression is associated with attenuated neutrophil differentiation and autophagy of NB4 APL cells.

Authors:  Julian Wampfler; Elena A Federzoni; Bruce E Torbett; Martin F Fey; Mario P Tschan
Journal:  J Leukoc Biol       Date:  2015-05-19       Impact factor: 4.962

7.  Aberrant expression of cyclin D1 in cancer.

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Sign Transduct Insights       Date:  2015-09-20

8.  Human DMTF1β antagonizes DMTF1α regulation of the p14(ARF) tumor suppressor and promotes cellular proliferation.

Authors:  Mario P Tschan; Elena A Federzoni; Aladin Haimovici; Christian Britschgi; Bettina A Moser; Jing Jin; Venkateshwar A Reddy; Dennis A Sheeter; Kimberlee M Fischer; Peiqing Sun; Bruce E Torbett
Journal:  Biochim Biophys Acta       Date:  2015-07-15

9.  PU.1 supports TRAIL-induced cell death by inhibiting NF-κB-mediated cell survival and inducing DR5 expression.

Authors:  Aladin Haimovici; Magali Humbert; Elena A Federzoni; Deborah Shan-Krauer; Thomas Brunner; Steffen Frese; Thomas Kaufmann; Bruce E Torbett; Mario P Tschan
Journal:  Cell Death Differ       Date:  2017-03-31       Impact factor: 15.828

10.  Prognostic value of the hDMP1-ARF-Hdm2-p53 pathway in breast cancer.

Authors:  D Maglic; S Zhu; E A Fry; P Taneja; F Kai; R D Kendig; T Sugiyama; L D Miller; M C Willingham; K Inoue
Journal:  Oncogene       Date:  2012-10-08       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.